Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. [electronic resource]
Producer: 20180116Description: 689-698 p. digitalISSN:- 1432-1041
- Adolescent
- Adult
- Agammaglobulinaemia Tyrosine Kinase
- Antigens, CD -- metabolism
- Antigens, Differentiation, T-Lymphocyte -- metabolism
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Drug Interactions
- Half-Life
- Humans
- Isoquinolines -- administration & dosage
- Lectins, C-Type -- metabolism
- Male
- Methotrexate -- administration & dosage
- Middle Aged
- Oligopeptides -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.